Acorda Therapeutics (ACOR) CEO Adopts Stock Trading Plan
More News related to ACOR
- Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis
- Acorda Therapeutics to Present at the UBS Global Life Sciences Conference
- Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting
- Acorda Therapeutics to Present at the Baird's 2008 Small Cap Health Care Conference
- Acorda Therapeutics to Present at the 3rd Annual Citi Biotech Day Conference
More News related to Insider Trades
- Chesapeake's (CHK) CEO McClendon Gets Wiped Out, Has To Sell Nearly All His Shares
- DSW (DSW) CEO Buys Another 653.6K Shares
- Discover Financial (DFS) CFO Buys 26K Shares
- AAR Corp. (AIR) Chairman/CEO Buys 10K Shares
- Life Time Fitness (LTM) Announces Pledge Of Stock Transactions by CEO
Acorda Therapeutics, Inc. (Nasdaq: ACOR) disclosed that Ron Cohen, President and CEO, adopted a pre-arranged trading plan.
The Plan provides for the sale of up to a total of 81,432 shares of common stock of the Company upon the exercise of vested stock options, beginning on the third day following the release of the Company’s first quarter 2008 quarterly earnings report and ending on November 7, 2008. Shares will be sold under the Plan on the open market at prevailing market prices, subject to minimum price thresholds. [LJ]
Related Categories
Insider TradesStocks Mentioned
-0.87Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
